• Thomas Kowalski, Ali Siddiqui, David Loren, Howard R Mertz, Damien Mallat, Nadim Haddad, Nidhi Malhotra, Brett Sadowski, Mark J Lybik, Sandeep N Patel, Emuejevoke Okoh, Laura Rosenkranz, Michael Karasik, Michael Golioto, Jeffrey Linder, Marc F Catalano, and Mohammad A Al-Haddad.
• *Department of Medicine, Jefferson Digestive Disease Institute, Thomas Jefferson University, Philadelphia, PA †Nashville GI Associates, Nashville, TN ‡Premier Gastroenterology of Texas **Digestive Health Associates of Texas, Dallas, TX §Division of Gastroenterology, Medstar Georgetown University Hospital, Washington, DC ∥Northside Gastroenterology, Indianapolis, IN ¶Department of Medicine, University of Texas San Antonio, San Antonio, TX #Connecticut GI, Hartford, CT ††Wisconsin Center for Advanced Research, St. Luke's Medical Center, Milwaukee, WI ‡‡Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
• J. Clin. Gastroenterol. 2016 Sep 1; 50 (8): 649-57.

GoalsTo examine the utility of integrated molecular pathology (IMP) in managing surveillance of pancreatic cysts based on outcomes and analysis of false negatives (FNs) from a previously published cohort (n=492).BackgroundIn endoscopic ultrasound with fine-needle aspiration (EUS-FNA) of cyst fluid lacking malignant cytology, IMP demonstrated better risk stratification for malignancy at approximately 3 years' follow-up than International Consensus Guideline (Fukuoka) 2012 management recommendations in such cases.StudyPatient outcomes and clinical features of Fukuoka and IMP FN cases were reviewed. Practical guidance for appropriate surveillance intervals and surgery decisions using IMP were derived from follow-up data, considering EUS-FNA sampling limitations and high-risk clinical circumstances observed. Surveillance intervals for patients based on IMP predictive value were compared with those of Fukuoka.ResultsOutcomes at follow-up for IMP low-risk diagnoses supported surveillance every 2 to 3 years, independent of cyst size, when EUS-FNA sampling limitations or high-risk clinical circumstances were absent. In 10 of 11 patients with FN IMP diagnoses (2% of cohort), EUS-FNA sampling limitations existed; Fukuoka identified high risk in 9 of 11 cases. In 4 of 6 FN cases by Fukuoka (1% of cohort), IMP identified high risk. Overall, 55% of cases had possible sampling limitations and 37% had high-risk clinical circumstances. Outcomes support more cautious management in such cases when using IMP.ConclusionsAdjunct use of IMP can provide evidence for relaxed surveillance of patients with benign cysts that meet Fukuoka criteria for closer observation or surgery. Although infrequent, FN results with IMP can be associated with EUS-FNA sampling limitations or high-risk clinical circumstances.

25 keywords...

hide…